Neuroregulation of appetite

Treatment of the Obese Patient

Volumn , Issue , 2014, Pages 3-22

  Reizes, Ofer ^a   Benoit, Stephen C ^b   Clegg, Deborah J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929923711     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1203-2_1     Document Type: Chapter

References (248)

1. Stellar E. The physiology of motivation. Psychol Rev. 1954;61:5-22.
2. Powley TL. The ventromedial hypothalamic syndrome, satiety, and a cephalic phase hypothesis. Psychol Rev. 1977;84:89-126.
3. Sclafani A. The role of hyperinsulinema and the vagus nerve in hypothalamic hyperphagia reexamined. Diabetologia. 1981;20(Suppl):402-10.
4. Bray GA, Sclafani A, Novin D. Obesity-inducing hypothalamic knife cuts: effects on lipolysis and blood insulin levels. Am J Physiol. 1982;243(3):R445-9.
5. Aravich PF, Sclafani A. Paraventricular hypothalamic lesions and medial hypothalamic knife cuts produce similar hyperphagia syndromes. Behav Neurosci. 1983;97(6):970-83.
6. Grill HJ, Norgren R. Chronically decerebrate rats demonstrate satiation but not bait shyness. Science. 1978;201(4352):267-9.
7. Grill HJ, Norgren R. The taste reactivity test. II. Mimetic responses to gustatory stimuli in chronic thalamic and chronic decerebrate rats. Brain Res. 1978;143(2):281-97.
8. Grill HJ, Smith GP. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol. 1988;254:R853-6.
9. Flynn FW, Grill HJ. Intraoral intake and taste reactivity responses elicited by sucrose and sodium chloride in chronic decerebrate rats. Behav Neurosci. 1988;102(6):934-41.
10. Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond (Biol). 1953;140:579-92.
11. Ahima RS, et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21:263-307.
12. Cone RD, et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord. 2001;25 Suppl 5:S63-7.
13. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999;22:221-32.
14. Schwartz MW, et al. Central nervous system control of food intake. Nature. 2000;404:661-71.
15. Havel PJ, et al. Gender differences in plasma leptin concentrations. Nat Med. 1996;2(9):949-50.
16. Ahren B, et al. Regulation of plasma leptin in mice: influence of age, high-fat diet and fasting. Am J Physiol. 1997;273:R113-20.
17. Havel PJ. Mechanisms regulating leptin production: implications for control of energy balance. Am J Clin Nutr. 1999;70:305-6.
18. Buchanan C, et al. Central nervous system effects of leptin. Trends Endocrinol Metab. 1998;9(4):146-50.
19. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14(12):1132-43.
20. Bjorntorp P. Abdominal fat distribution and the metabolic syndrome. J Cardiovasc Pharmacol. 1992;20 Suppl 8:S26-8.
21. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 1997;13:795-803.
22. Woods SC, et al. Signals that regulate food intake and energy homeostasis. Science. 1998;280:1378-83.
23. Schwartz MW, et al. Insulin in the brain: A hormonal regulator of energy balance. Endocr Rev. 1992;13: 387-414.
24. de Castro JM, Stroebele N. Food intake in the real world: implications for nutrition and aging. Clin Geriatr Med. 2002;18:685-97.
25. de Castro JM. The control of eating behavior in free living humans. In: Stricker EM, Woods SC, editors. Handbook of neurobiology. Neurobiology of food andfluid intake, vol. 14(2). New York: Kluwer Academic, Plenum; 2004. p. 467-502.
26. de Graaf C, et al. Biomarkers of satiation and satiety. Am J Clin Nutr. 2004;79:946-61.
27. Mayer J. Regulation of energy intake and the body weight: The glucostatic and lipostatic hypothesis. Ann NY Acad Sci. 1955;63:14-42.
28. Mayer J, Thomas DW. Regulation of food intake and obesity. Science. 1967;156:328-37.
29. Friedman MI. Fuel partitioning and food intake. Am J Clin Nutr. 1998;67 Suppl 3:513S-8.
30. Friedman MI. An energy sensor for control of energy intake. Proc Nutr Soc. 1997;56(1A):41-50.
31. Langhans W. Metabolic and glucostatic control of feeding. Proc Nutr Soc. 1996;55:497-515.
32. Peters A, et al. The selfish brain: competition for energy resources. Neurosc Biobehav Rev. 2004;28: 143-80.
33. Strubbe JH, Woods SC. The timing of meals. Psychol Rev. 2004;111:128-41.
34. Woods SC, Strubbe JH. The psychobiology of meals. Psychon Bull Rev. 1994;1:141-55.
35. Woods SC, et al. Food intake and the regulation of body weight. Annu Rev Psychol. 2000;51:255-77.
36. Davis JD, Campbell CS. Peripheral control of meal size in the rat. Effect of sham feeding on meal size and drinking rate. J Comp Physiol Psychol. 1973; 83(3):379-87.
37. Davis JD, Smith GP. Learning to sham feed: behavioral adjustments to loss of physiological postingestional stimuli. Am J Physiol. 1990;259(6 Pt 2): R1228-35.
38. Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastricfistulas. Nature. 1973;245:323-5.
39. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84:488-95.
40. Kissileff HR, et al. Cholecystokinin decreases food intake in man. Am J Clin Nutr. 1981;34:154-60.
41. Muurahainenn N, et al. Effects of cholecystokininoctapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav. 1988;44:644-9.
42. Moran TH, Schwartz GJ. Neurobiology of cholecystokinin. Crit Rev Neurobiol. 1994;9:1-28.
43. Smith GP, Gibbs J. The development and proof of the cholecystokinin hypothesis of satiety. In: Dourish CT et al., editors. Multiple cholecystokinin receptors in the CNS. Oxford: Oxford University Press; 1992. p. 166-82.
44. Beglinger C, et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol. 2001;280: R1149-54.
45. Hewson G, et al. The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of endogenous cholecystokinin. Br J Pharmacol. 1988;93:79-84.
46. Moran TH, et al. Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am J Physiol. 1993;265:R620-4.
47. Reidelberger RD, O'Rourke MF. Potent cholecystokinin antagonist L-364,718 stimulates food intake in rats. Am J Physiol. 1989;257:R1512-8.
48. Kaplan JM, Moran TH. Gastrointestinal signaling in the control of food intake. In: Stricker M, Woods SC, editors. Handbook of behavioral neurobiology. Neurobiology of food andfluid intake, vol. 4(2). New York: Kluwer Academic, Plenum; 2004. p. 273-303.
49. Smith GP, editor. Satiation: from gut to brain. New York: Oxford University Press; 1998.
50. Stein LJ, Woods SC. Gastrin releasing peptide reduces meal size in rats. Peptides. 1982;3(5):833-5.
51. Ladenheim EE, Wirth KE, Moran TH. Receptor subtype mediation of feeding suppression by bombesinlike peptides. Pharmacol Biochem Behav. 1996;54(4):705-11.
52. Okada S, et al. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectively reduces fat intake. Physiol Behav. 1991;49: 1185-9.
53. Shargill NS, et al. Enterostatin suppresses food intake following injection into the third ventricle of rats. Brain Res. 1991;544:137-40.
54. Lotter EC, et al. Somatostatin decreases food intake of rats and baboons. J Comp Physiol Psychol. 1981;95(2):278-87.
55. Larsen PJ, et al. Systemic administration of the longacting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50:2530-9.
56. Naslund E, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999;23(3): 304-11.
57. Fujimoto K, et al. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity in rats. Brain Res. 1993;608:233-7.
58. Batterham RL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002; 418(6898):650-4.
59. Chance WT, et al. Anorexia following the intrahypothalamic administration of amylin. Brain Res. 1991;539(2):352-4.
60. Lutz TA, Del Prete E, Scharrer E. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav. 1994;55(5):891-5.
61. Geary N. Glucagon and the control of meal size. In: Smith GP, editor. Satiation: from gut to brain. New York: Oxford University Press; 1998. p. 164-97.
62. Salter JM. Metabolic effects of glucagon in the Wistar rat. Am J Clin Nutr. 1960;8:535-9.
63. Davison JS, Clarke GD. Mechanical properties and sensitivity to CCK of vagal gastric slowly adapting mechanoreceptors. Am J Physiol. 1988;255(1 Pt 1): G55-61.
64. Lorenz DN, Goldman SA. Vagal mediation of the cholecystokinin satiety effect in rats. Physiol Behav. 1982;29(4):599-604.
65. Moran TH, et al. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol. 1997;272(4 Pt 2):R1245-51.
66. Geary N, Le Sauter J, Noh U. Glucagon acts in the liver to control spontaneous meal size in rats. Am J Physiol. 1993;264:R116-22.
67. Langhans W. Role of the liver in the metabolic control of eating: what we know-and what we do not know. Neurosci Biobehav Rev. 1996;20:145-53.
68. Lutz TA, Del Prete E, Scharrer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides. 1995;16(3):457-62.
69. Lutz TA, et al. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides. 1998;19(2):309-17.
70. Edwards GL, Ladenheim EE, Ritter RC. Dorsomedial hindbrain participation in cholecystokinin-induced satiety. Am J Physiol. 1986;251:R971-7.
71. Moran TH, Ladenheim EE, Schwartz GJ. Withinmeal gut feedback signaling. Int J Obes Relat Metab Disord. 2001;25 Suppl 5:S39-41.
72. Moran TH, Kinzig KP. Gastrointestinal satiety signals. II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):G183-8.
73. Rinaman L, et al. Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats. J Comp Neurol. 1995;360:246-56.
74. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol. 1984;246:R776-87.
75. West DB, et al. Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite. 1987;8:221-7.
76. Moran TH, et al. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol. 1998;274(3 Pt 2):R618-25.
77. Birch LL, et al. The variability of young children's energy intake. N Engl J Med. 1991;324:232-5.
78. de Castro JM. Prior day's intake has macronutrientspecific delayed negative feedback effects on the spontaneous food intake of free-living humans. J Nutr. 1998;128:61-7.
79. Gasnier A, Mayer A. Recherche sur la régulation de la nutrition. II. Mécanismes régulateurs de la nutrition chez le lapin domestique. Ann Physiol Physicochem Biol. 1939;15:157-85.
80. Barrachina MD, et al. Synergistic interaction between leptin and cholecystokinin to reduce shortterm food intake in lean mice. Proc Natl Acad Sci USA. 1997;94:10455-60.
81. Figlewicz DP, et al. Intraventricular insulin enhances the meal-suppressive efficacy of intraventricular cholecystokinin octapeptide in the baboon. Behav Neurosci. 1995;109:567-9.
82. Matson CA, et al. Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides. 1997;18:1275-8.
83. Matson CA, et al. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol. 2000;278:R882-90.
84. Riedy CA, et al. Central insulin enhances sensitivity to cholecystokinin. Physiol Behav. 1995;58:755-60.
85. Schwartz GJ, Moran TH. Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Neurosci Biobehav Rev. 1996;20:47-56.
86. Schwartz GJ, et al. Relationships between gastric motility and gastric vagal afferent responses to CCK and GRP in rats differ. Am J Physiol. 1997;272(6 Pt 2):R1726-33.
87. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol. 2002;23(1):2-40.
88. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337-50.
89. Porte DJ, et al. Obesity, diabetes and the central nervous system. Diabetologia. 1998;41:863-81.
90. Woods SC, et al. Insulin and the blood-brain barrier. Curr Pharm Des. 2003;9:795-800.
91. Tartaglia LA, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83:1263-71.
92. Bruning JC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122-5.
93. Seeley R, et al. Melanocortin receptors in leptin effects. Nature. 1997;390:349.
94. Ollmann M, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997;278(5335):135-8.
95. Rossi M, et al. A C-terminal fragment of Agoutirelated protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 1998;139:4428-31.
96. Hagan MM, et al. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol. 2000;279:R47-52.
97. Fan W, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385:165-8.
98. Hagan M, et al. Role of the CNS melanocortin system in the response to overfeeding. J Neurosci. 1999;19:2362-7.
99. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol. 2003;24:1-10.
100. Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272:6093-6.
101. Vaisse C, et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet. 1996;14(1):95-7.
102. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996;274(5290): 1185-8.
103. Benoit SC, et al. Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents. J Clin Invest. 2009;119(9):2577-89.
104. Ainscow EK, et al. Dynamic imaging of free cytosolic ATP concentration during fuel sensing by rat hypothalamic neurones: evidence for ATPindependent control of ATP-sensitive K(+) channels. J Physiol. 2002;544:429-45.
105. Even P, Nicolaidis S. Spontaneous and 2DG-induced metabolic changes and feeding: The ischymetric hypothesis. Brain Res Bull. 1985;15:429-35.
106. Nicolaidis S, Even P. Mesure du métabolisme de fond en relation avec la prise alimentaire: Hypothese iscymétrique. C R Acad Sci Paris. 1984;298: 295-300.
107. Clegg DJ, et al. Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes. 2002;51(11):3196-201.
108. Kumar MV, et al. Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proc Natl Acad Sci USA. 2002;99:1921-5.
109. Loftus TM, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000;288:2299-300.
110. Obici S, et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9:756-61.
111. Wortman MD, et al. C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med. 2003;9:483-5.
112. Obici S, et al. Central administration of oleic acid inhibits glucose production and food intake. Diabetes. 2002;51(2):271-5.
113. Nicolaidis S. Mecanisme nerveux de l'equilibre energetique. Journees Annuelles de Diabetologie de l'Hotel-Dieu. 1978;1:152-6.
114. Levin BE, Dunn-Meynell AA, Routh VH. Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Am J Physiol. 1999;276: R1223-31.
115. Levin BE. Glucosensing neurons as integrators of metabolic signals. EWCBR. 2002;22:67.
116. Clark JT, et al. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology. 1984;115(1):427-9.
117. Stanley BG, Leibowitz SF. Neuropeptide Y injected into the paraventricular hypothalamus: A powerful stimulant of feeding behavior. Proc Natl Acad Sci USA. 1984;82:3940-3.
118. Seeley RJ, Payne CJ, Woods SC. Neuropeptide Y fails to increase intraoral intake in rats. Am J Physiol. 1995;268:R423-7.
119. Allen YS, et al. Neuropeptide Y distribution in the rat brain. Science. 1983;221:877-9.
120. Minth CD, Andrews PC, Dixon JE. Characterization, sequence and expression of the cloned human neuropeptide Y gene. J Biol Chem. 1986;261(26): 11975-9.
121. Mizuno TM, et al. Fasting regulates hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelanocortin in diabetic mice independent of changes in leptin or insulin. Endocrinology. 1999; 140(10):4551-7.
122. Sahu A, et al. Neuropeptide Y release from the parventricular nucleus increases in association with hyperphagia in streptozotocin-induced diabetic rats. Endocrinology. 1992;131(6):2979-85.
123. Marks JL, et al. Effect of fasting on regional levels of neuropeptide Y mRNA and insulin receptors in the rat hypothalamus: an autoradiographic study. Mol Cell Neurosci. 1992;3:199-205.
124. Sahu A, et al. Neuropeptide Y concentration in microdissected hypothalamic regions and in vitro release from the medial basal hypothalamus-preoptic area of streptozotocin-diabetic rats with and without insulin substitution therapy. Endocrinology. 1990; 126:192-8.
125. Kalra SP, et al. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA. 1991;88:10931-5.
126. Sahu A, Kalra PS, Kalra SP. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides. 1988;9:83-6.
127. Stanley BG, et al. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides. 1986;7:1189-92.
128. McMinn JE, et al. NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. Regul Pept. 1998;75-76:425-31.
129. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes. 1995;44:147-51.
130. Sipols AJ, Baskin DG, Schwartz MW. The importance of central nervous system insulin deficiency to diabetic hyperphagia. Diabetes. 1993;42 Suppl 1:152.
131. Stephens TW, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377:530-4.
132. Schwartz MW, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes. 1996;45:531-5.
133. Bernardis LL, Bellinger LL. The dorsomedial hypothalamic nucleus revisited: 1998 update. Proc Soc Exp Biol Med. 1998;218(4):284-306.
134. Kesterson RA, et al. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol. 1997;11(5):630-7.
135. Guan XM, et al. Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. Neuroreport. 1998;9(15):3415-9.
136. Bi S, Ladenheim EE, Moran TH. Elevated neuropeptide Y expression in the dorsomedial hypothalamic nucleus may contribute to the hyperphagia and obesity in OLETF rats with CCKA receptor deficit. In Annual Meeting for the Society for Neuroscience, New Orleans, LA. 2000.
137. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 1996;381:415-8.
138. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science. 1996;274(5293):1704-7.
139. Hollopeter G, Erickson JC, Palmiter RD. Role of neuropeptide Y in diet-, chemical-and geneticinduced obesity of mice. Int J Obes Relat Metab Disord. 1998;22(6):506-12.
140. Palmiter RD, et al. Life without neuropeptide Y. Recent Prog Horm Res. 1998;53:163-99.
141. Woods SC, et al. NPY and food intake: discrepancies in the model. Regul Pept. 1998;75-76:403-8.
142. Gropp E, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci. 2005;8(10):1289-91.
143. Criscione L, et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest. 1998;102(12): 2136-45.
144. Marsh DJ, et al. Role of the Y5 neuropeptide Y receptor in feeding and obesity [see comments]. Nat Med. 1998;4(6):718-21.
145. Kanatani A, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology. 2000;141(3):1011-6.
146. Tang-Christensen M, et al. Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J Endocrinol. 1998;159(2):307-12.
147. Larsen PJ, et al. Activation of central neuropeptide Y Y1 receptors potently stimulates food intake in male rhesus monkeys [In Process Citation]. J Clin Endocrinol Metab. 1999;84(10):3781-91.
148. Hellig M, et al. In vivo downregulation of neuropeptide Y (NPY) Y1-receptors by i.c.v. antisense oligodeoxynucleotide administration is associated with signs of anxiety in rats. Soc Neurosci Abst. 1992;18:1539.
149. O'Shea D, et al. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology. 1997;138(1):196-202.
150. Zimanyi IA, Fathi Z, Poindexter GS. Central control of feeding behavior by neuropeptide Y. Curr Pharm Des. 1998;4(4):349-66.
151. Levens NR, Della-Zuana O. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs. Curr Opin Investig Drugs. 2003;4(10):1198-204.
152. Qu D, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature. 1996;380(6571):243-7.
153. Ludwig D, et al. Melanin-concentrating hormone: A functional melanocortin antagonist in the hypothalamus. Am J Physiol. 1998;274:E627-33.
154. Sanchez M, Baker B, Celis M. Melaninconcentrating hormone (MCH) antagonizes the effects of alpha-MSH and neuropeptide E-I on grooming and locomotor activities in the rat. Peptides. 1997;18:393-6.
155. Clegg DJ, et al. Intraventricular melaninconcentrating hormone stimulates water intake independent of food intake. Am J Physiol Regul Integr Comp Physiol. 2003;284(2):R494-9.
156. Rossi M, et al. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology. 1997;138(1):351-5.
157. Shimada M, et al. Mice lacking melaninconcentrating hormone are hypophagic and lean. Nature. 1998;396:670-4.
158. Mystkowski P, et al. Hypothalamic melaninconcentrating hormone and estrogen-induced weight loss [In Process Citation]. J Neurosci. 2000;20(22): 8637-42.
159. Mashiko S, et al. Antiobesity effect of a melaninconcentrating hormone 1 receptor antagonist in dietinduced obese mice. Endocrinology. 2005;146(7): 3080-6.
160. Takekawa S, et al. T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol. 2002;438(3): 129-35.
161. de Lecea L, et al. The hypocretins: hypothalamusspecific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322-7.
162. Sakurai T, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-85.
163. Broberger C, et al. Hypocretin/orexin-and melaninconcentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti generelated protein systems. J Comp Neurol. 1998;402: 460-74.
164. Yamanaka A, et al. Orexin-induced food intake involves neuropeptide Y pathway. Brain Res. 2000;859(2):404-9.
165. Rauch M, et al. Orexin A activates leptin-responsive neurons in the arcuate nucleus [In Process Citation]. Pflugers Arch. 2000;440(5):699-703.
166. Peyron C, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
167. Kilduff TS, Peyron C. The hypocretin/orexin ligandreceptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23(8):359-65.
168. Elias CF, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol. 1998;402(4): 442-59.
169. Tritos NA, et al. Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes. 1998;47:1687-92.
170. Jain MR, et al. Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regul Pept. 2000;87(1-3): 19-24.
171. Sergeyev V, et al. Effect of 2-mercaptoacetate and 2-deoxy-D-glucose administration on the expression of NPY, AGRP, POMC, MCH and hypocretin/orexin in the rat hypothalamus. Neuroreport. 2000;11(1): 117-21.
172. Choi DL, et al. Orexin signaling in the paraventricular thalamic nucleus modulates mesolimbic dopamine and hedonic feeding in the rat. Neuroscience. 2012;210:243-8.
173. Kojima M, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature. 1999;402(6762):656-60.
174. Kojima M, Hosoda H, Kangawa K. Purification and distribution of ghrelin: The natural endogenous ligand for the growth hormone secretagogue receptor. Horm Res. 2001;56 Suppl 1:93-7.
175. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806): 908-13.
176. Kamegai J, et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology. 2000;141(12):4797-800.
177. Wren AM, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992.
178. Horvath TL, et al. Minireview: Ghrelin and the regulation of energy balance-A hypothalamic perspective. Endocrinology. 2001;142(10):4163-9.
179. Asakawa A, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120(2):337-45.
180. Kamegai J, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agoutirelated protein mRNA levels and body weight in rats. Diabetes. 2001;50(11):2438-43.
181. Nakazato M, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817): 194-8.
182. Wang L, Saint-Pierre DH, Tache Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett. 2002;325(1):47-51.
183. Tschöp M, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4): 707-9.
184. Cummings DE, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623-30.
185. Tong J, et al. Acute administration of unacylated ghrelin has no effect on basal or stimulated insulin secretion in healthy humans. Diabetes. 2014.
186. Davis JF, et al. GOAT induced ghrelin acylation regulates hedonic feeding. Horm Behav. 2012;62(5): 598-604.
187. Yi CX, et al. The GOAT-ghrelin system is not essential for hypoglycemia prevention during prolonged calorie restriction. PLoS One. 2012;7(2):e32100.
188. Horvath TL, Diano S, Tschop M. Ghrelin in hypothalamic regulation of energy balance. Curr Top Med Chem. 2003;3(8):921-7.
189. Asakawa A, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 2003;52(7):947-52.
190. Beck B, Richy S, Stricker-Krongrad A. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci. 2004;76(4):473-8.
191. Bernstein IL, Lotter EC, Kulkosky PJ. Effect of force-feeding upon basal insulin levels in rats. Proc Soc Exp Biol Med. 1975;150:546-8.
192. Seeley RJ, et al. Behavioral, endocrine and hypothalamic responses to involuntary overfeeding. Am J Physiol. 1996;271:R819-23.
193. Elias CF, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron. 1998; 21:1375-85.
194. Kristensen P, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 1998; 393:72-6.
195. Lambert PD, et al. CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse. 1998;29:293-8.
196. Vrang N, et al. Recombinant CART peptide induces c-Fos expression in central areas involved in control of feeding behaviour. Brain Res. 1999;818:499-509.
197. Kask A, et al. Anorexigenic cocaine-and amphetamine-regulated transcript peptide intensifies fear reactions in rats. Brain Res. 2000;857(1-2): 283-5.
198. Abbott CR, et al. Evidence of an orexigenic role for cocaine-and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology. 2001;142(8):3457-63.
199. Krahn DD, Gosnell BA. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res. 1988;443: 63-9.
200. Arase K, et al. Effects of corticotropin releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol. 1988;255:E255-9.
201. Heinrichs S, et al. Corticotropin-releasing factorbinding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci USA. 1996;93:15475-80.
202. Spina M, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 1996; 273:1561-4.
203. Vaughan J, et al. Urocortin, a mammalian neuropeptide related tofish urotensin I and to corticotropinreleasing factor [see comments]. Nature. 1995;378: 287-92.
204. Richard D, Huang Q, Timofeeva E. The corticotropinreleasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S36-9.
205. Heinrichs SC, Richard D. The role of corticotropinreleasing factor and urocortin in the modulation of ingestive behavior. Neuropeptides. 1999;33(5):350-9.
206. D'Alessio DA, et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest. 1996;97(1):133-8.
207. Drucker DJ, et al. Biologic properties and therapeutic potential of glucagon-like peptide-2. JPEN J Parenter Enteral Nutr. 1999;23(5 Suppl):S98-100.
208. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47(2):159-69.
209. van Dijk G, Thiele TE. Glucagon-like peptide-1 (7-36) amide: A central regulator of satiety and interoceptive stress. Neuropeptides. 1999;33(5):406-14.
210. Goldstone AP, et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem Biophys Res Commun. 2000; 269(2):331-5.
211. Elmquist JK, et al. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology. 1997;138:839-42.
212. Turton MD, et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature. 1996;379(6560):69-72.
213. Tang-Christensen M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 Pt 2):R848-56.
214. Van Dijk G, et al. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol. 1996;271(4 Pt 2): R1096-100.
215. Thiele TE, et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol. 1997;272(2 Pt 2):R726-30.
216. Thiele TE, et al. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res. 1998;801(1-2):164-70.
217. Seeley RJ, et al. The role of CNS GLP-1-(7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci. 2000;20:1616-21.
218. Tang-Christensen M, et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000;6(7):802-7.
219. Halford JC, et al. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets. 2005;6(2):201-13.
220. Lawton CL, Blundell JE. The effect of d-fenfluramine on intake of carbohydrate supplements is influenced by the hydration of the test diets. Behav Pharmacol. 1992;3(5):517-23.
221. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry. 1998;44(9):851-64.
222. Pierce PA, et al. 5-Hydroxytryptamine receptor subtype messenger RNAs in human dorsal root ganglia: A polymerase chain reaction study. Neuroscience. 1997;81(3):813-9.
223. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv. 2005;5(5):282-91.
224. Nonogaki K, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998;4(10): 1152-6.
225. Heisler LK, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002; 297(5581):609-11.
226. Ettinger MP, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: A randomized, dose-ranging study. JAMA. 2003; 289(14):1826-32.
227. Anderson KD, et al. Activation of the hypothalamic arcuate nucleus predicts the anorectic actions of ciliary neurotrophic factor and leptin in intact and gold thioglucose-lesioned mice. J Neuroendocrinol. 2003;15(7):649-60.
228. Kelly JF, et al. Ciliary neurotrophic factor and leptin induce distinct patterns of immediate early gene expression in the brain. Diabetes. 2004;53(4): 911-20.
229. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science. 2005;310(5748):679-83.
230. Pu S, et al. Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor. J Neuroendocrinol. 2000;12(9):827-32.
231. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5): 571-8.
232. Yen T, et al. Obesity, diabetes, and neoplasia in yellow A(vy)/-mice: ectopic expression of the agouti gene. FASEB J. 1994;8:479-88.
233. Zimanyi IA, Pelleymounter MA. The role of melanocortin peptides and receptors in regulation of energy balance. Curr Pharm Des. 2003;9(8): 627-41.
234. Stutz AM, Morrison CD, Argyropoulos G. The Agouti-related protein and its role in energy homeostasis. Peptides. 2005;26(10):1771-81.
235. Yaswen L, et al. Obesity in the mouse model of proopiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5(9):1066-70.
236. Krude H, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2): 155-7.
237. Huszar D, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131-41.
238. Cone RD, et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996;51: 287-320.
239. Seeley RJ, Drazen DL, Clegg DJ. The critical role of the melanocortin system in the control of energy balance. Annu Rev Nutr. 2004;24:133-49.
240. Boyce RS, Duhl DM. Melanocortin-4 receptor agonists for the treatment of obesity. Curr Opin Investig Drugs. 2004;5(10):1063-71.
241. Bluher S, et al. Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes. 2004;53(11): 2787-96.
242. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84.
243. Davis JF, Choi DL, Benoit SC. Insulin, leptin and reward. Trends Endocrinol Metab. 2010;21(2):68-74.
244. Figlewicz DP, et al. Moderate high fat diet increases sucrose self-administration in young rats. Appetite. 2013;61(1):19-29.
245. Choi DL, et al. The role of orexin-A in food motivation, reward-based feeding behavior and foodinduced neuronal activation in rats. Neuroscience. 2010;167(1):11-20.
246. Benoit SC, et al. Novel functions of orexigenic hypothalamic peptides: from genes to behavior. Nutrition. 2008;24(9):843-7.
247. Davis JF, et al. Role for dopamine-3 receptor in the hyperphagia of an unanticipated high-fat meal in rats. Pharmacol Biochem Behav. 2006;85(1):190-7.
248. Davis JF, et al. Leptin regulates energy balance and motivation through action at distinct neural circuits. Biol Psychiatry. 2011;69(7):668-74.